Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India
State: Central
Ministry: Ministry Of Chemicals And Fertilizers
Department: Department Of Pharmaceuticals
Category: Business & Entrepreneurship
Beneficiary Type: Business Entity, Industries

The objective of the Scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the Scheme, financial incentives shall be given based on threshold investment and domestic sales made by selected applicant for the eligible products.

Benefits:
> **Financial Incentive on Sales:**

- Incentive is provided on sales of 41 identified products for 6 years.

> **Target Segments:** 

- Four Target Segments covering 41 products are listed in [**Annexure B.**](https://plibulkdrugs.ifciltd.com/docs/Gazettee%20notification%20of%20bulk%20drug%20schemes.pdf)
> **For Fermentation-Based Products:**

- 20% incentive from FY 2023-24 to FY 2026-27.
- 15% incentive in FY 2027-28.
- 5% incentive in FY 2028-29.

> **For Chemical Synthesis-Based Products:**

- 10% incentive from FY 2022-23 to FY 2027-28.

> **Coverage of Products:**

- Incentives applicable for 41 products covering 53 critical APIs.

<br>

Eligibility:
- **Applicability:** The scheme is applicable only for greenfield projects.

- **Eligibility**

1. Support under the scheme shall be provided only to manufacturers of critical KSMs/DIs and APIs registered in India.
1. Eligibility shall be subject to threshold investment in green field projects as given in the below-table.
1. Eligibility under the scheme shall not affect eligibility under any other scheme and vice-versa.

> **Eligibility Threshold Criteria:**

**S. No****Segment****Threshold Investment**1.Fermentation based 04 KSMs /Drug Intermediates₹400,00,00,000/-2.Fermentation based 10 niche KSMs / Drug Intermediates / APIs₹50,00,00,000/-3.Key Chemical Synthesis based 04 KSMs /Drug Intermediates₹50,00,00,000/-4.Other 23 Chemical Synthesis based KSMs / Drug Intermediates / APIs₹20,00,00,000/-<br>

<br>

Application Process:
[Online]
The eligible applicants may apply through online mode only. The link is: https://plibulkdrugs.ifciltd.com/login
Contact: Click here.Application Fee under the Scheme:
S. No.Name of the Eligible ProductApplication Fee1.Penicillin G, 7-ACA, Erythromycin Thiocynate (TIOC), Clavulanic Acid₹1,00,000/-2.All other eligible products₹50,000/-Application Fee will be paid electronically through NEFT / RTGS to the bank account as per details given hereunder:
Bank Account Name : IFCI – PLI – Bulk DrugsAccount Number : 3859475896Name of the Bank : Central Bank of IndiaIFSC Code : CBIN0281410Branch Code : 1410Branch Name : Nehru PlaceBank Address : Central Bank of India, 59, Shakuntala Building, Nehru Place, New Delhi - 110019

Documents Required:
Constitution of Business: Copy of the memorandum and articles of association or equivalent registration document, Partnership Deed and any equivalent document. Shareholding pattern, share of the partners as the case may be.
Business Details:
Self-certified copies of PAN, GST Certificate for applicant.
Self-certified copies of brief profile of Chairman, CEO, CXOs, Promoter and Key Managerial Persons along with their PAN / DIN.
Self-certified copies of Annual Reports including Annual Financial Reports along with schedules, audited and complete Balance Sheet, as the case may be for 3 years. Most recent reports are to be provided.
Credit History: Certificate from Company Secretary / Board of Directors/ Managing Partner or Owner of the Proprietorship Firm.
Key Personnel Details: Contact details of three senior employees of applicant. Details would include Name, Designation, Address, phone, email.
Net Worth of the Applicant and/ or group companies as on the date of application: Certificate from Statutory Auditor or Independent Chartered Accountant, as the case may be.
Financial Details (self-certified) (last 3 years).
Research and Development facility.
Project Details.
Domestic Value Addition.
Project Report for eligible product.
Application Fee Details.
Note: Detailed information regarding the documentation for the application process is available in the Guidelines (Annexure 1).